Vistagen Therapeutics Inc Revenue Growth Rates (VTGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vistagen Therapeutics Inc   (NASDAQ: VTGN)
 

VTGN's Revenue Growth by Quarter and Year

Vistagen Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VTGN Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 1.48
FY 1.48

VTGNs Annual Revenue
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2026 $ 1.27 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2025 $ 0.49 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2024 $ 1.06 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2022 $ 1.11 millions




VTGN Revenue first quarter 2027 Y/Y Growth Comment
Vistagen Therapeutics Inc achieved in the first quarter 2027, above Company average Revenue surge of 515% year on year, to $ 1.48 millions.

Looking into first quarter 2027 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Vistagen Therapeutics Inc ' s Revenue doubling of 515% ranks overall at the positon no. 506 in the first quarter 2027.


VTGN Revenue ( Y/Y Growth %) 2027
 2026 2025 2024
4th Quarter March - - - 11.11 %
3rd Quarter December - 30.43 % -43.9 % 127.78 %
2nd Quarter September - 44.44 % -35.71 % -
1st Quarter June 515 % 200 % -55.56 % -41.94 %
FY   - 168.09 % -56.07 % -

Financial Statements
Vistagen Therapeutics Inc 's first quarter 2027 Revenue $ 1.48 millions VTGN's Income Statement
Vistagen Therapeutics Inc 's first quarter 2026 Revenue $ 0.24 millions Quarterly VTGN's Income Statement


VTGN Revenue (Quarter on Quarter Growth %)

 2027
 2026 2025 2024
4th Quarter March - 53.33 % - -51.22 %
3rd Quarter December - 15.38 % 27.78 % 46.43 %
2nd Quarter September - 8.33 % 125 % 55.56 %
1st Quarter June 220.87 % - -60 % 0 %
FY (Year on Year)   - 168.09 % -56.07 % -


Back to VTGN Growth rate Comparisons >> Back to VTGN Growth rate Comparisons >>


Revenue first quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #122
Overall #506

Revenue Y/Y Growth Statistics
High Average Low
287.15 % -19.5 % -133.8 %
(Jun 30 2026)   (Jun 30 2023)
Revenue first quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #122
Overall #506
Revenue Y/Y Growth Statistics
High Average Low
287.15 % -19.5 % -133.8 %
(Jun 30 2026)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Vistagen Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
19730.87 % 703.4 % -100 %
(Mar 31 2012)  


VTGN's I. Quarter Q/Q Revenue Comment
Vistagen Therapeutics Inc achieved in the I. Quarter 2027 below company average Revenue doubling of 220.87% quarter on quarter, to $ 1.48 millions.

I. Quarter 2027 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Vistagen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 82.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #32
Overall #82
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #32
Overall #82
Revenue Q/Q Growth Statistics
High Average Low
19730.87 % 703.4 % -100 %
(Mar 31 2012)  


VTGN's I. Quarter Q/Q Revenue Comment
Vistagen Therapeutics Inc achieved in the I. Quarter 2027 below company average Revenue doubling of 220.87% quarter on quarter, to $ 1.48 millions.

I. Quarter 2027 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Vistagen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 82.


Vistagen Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2.50 $ 1.27 $ 0.79 $ 0.72 $ 0.65
Y / Y Revenue Growth (TTM) 287.15 % 161.11 % 13.13 % -17.67 % -33.43 %
Year on Year Revenue Growth Overall Ranking # 3512 # 3218 # 2365 # 2973 # 2856
Seqeuential Revenue Change (TTM) 97.08 % 60.63 % 9.57 % 11.61 % 32.92 %
Seq. Revenue Growth (TTM) Overall Ranking # 506 # 3221 # 2229 # 2504 # 2399


Cumulative Revenue growth Comment
With 287.15% annual Revenue growth, Vistagen Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3512.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 477
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
287.15 %
 -19.5 %
-133.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 122
S&P 500 # 506
Cumulative Revenue growth Comment
With 287.15% annual Revenue growth, Vistagen Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3512.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 477
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
287.15 %
-19.5 %
-133.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 122
S&P 500 # 506




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VTGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Abeona Therapeutics Inc 697.48%$ 697.477 millions
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions


About Vistagen Therapeutics Inc Revenue Growth Rates (VTGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vistagen Therapeutics Inc (CIK 1411685).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-057116
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vistagen Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.